Table 2. Multivariate analysis for OS in... | American Society of Hematology

Table 2.

Multivariate analysis for OS in patients with ATL

Variables	n	HR	95% CI	P
Sex
Male	59	1.000		Reference
Female	42	0.728	0.381-1.392	.337
Age, y
≤70	64	1.000		Reference
>70	37	1.170	0.663-2.066	.588
Clinical subtype
Chronic, smoldering	15	1.000		Reference
Acute, lymphoma	86	3.727	1.206-11.520	.022
ECOG PS
0,1	73	1.000		Reference
2-4	28	1.374	0.738-2.557	.316
sIL-2R, U/mL
≤20 000	82	1.000		Reference
>20 000	19	3.970	1.985-7.942	<.001
CD2⁻CD19⁺cells, %*
>0.15	81	1.000		Reference
≤0.15	20	2.157	1.105-4.210	.024
CD3⁺CD8⁺cells, %*
>1.65	81	1.000		Reference
≤1.65	20	1.768	0.787-3.973	.167
CD16⁺CD56⁺cells, %*
>1.36	81	1.000		Reference
≤1.36	20	2.343	0.997-5.509	.051
CD11c⁺monocytes, %†
>15.5	81	1.000		Reference
≤15.5	20	0.785	0.335-1.840	.578

Variables	n	HR	95% CI	P
Sex
Male	59	1.000		Reference
Female	42	0.728	0.381-1.392	.337
Age, y
≤70	64	1.000		Reference
>70	37	1.170	0.663-2.066	.588
Clinical subtype
Chronic, smoldering	15	1.000		Reference
Acute, lymphoma	86	3.727	1.206-11.520	.022
ECOG PS
0,1	73	1.000		Reference
2-4	28	1.374	0.738-2.557	.316
sIL-2R, U/mL
≤20 000	82	1.000		Reference
>20 000	19	3.970	1.985-7.942	<.001
CD2⁻CD19⁺cells, %*
>0.15	81	1.000		Reference
≤0.15	20	2.157	1.105-4.210	.024
CD3⁺CD8⁺cells, %*
>1.65	81	1.000		Reference
≤1.65	20	1.768	0.787-3.973	.167
CD16⁺CD56⁺cells, %*
>1.36	81	1.000		Reference
≤1.36	20	2.343	0.997-5.509	.051
CD11c⁺monocytes, %†
>15.5	81	1.000		Reference
≤15.5	20	0.785	0.335-1.840	.578

The patients were censored at the day of allogeneic HSCT.

The percentage among whole lymphocytes in PBMCs.

The percentage among whole monocytes in PBMCs.